{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:10:47Z","timestamp":1783487447287,"version":"3.55.0"},"reference-count":33,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":3372,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Hypothyroidism due to non-compliance with levothyroxine therapy (pseudomalabsorption) is rare. The diagnosis is considered in patients with persistent severe hypothyroidism despite treatment with large doses of levothyroxine. Intestinal malabsorption, drug and dietary interference with levothyroxine absorption and nephrotic syndrome should be excluded. The diagnosis of pseudomalabsorption can be demonstrated by using \u201can oral 1,000 \u00b5g of levothyroxine test\u201d showing a rapid decrease in thyroid-stimulating hormone and increase in thyroxine. There are however few data on the sensitivity and specificity of the test in large cohorts of hypothyroid patients. Treatment of pseudomalabsorption is controversial, with reports using parenteral, intramuscular or single weekly oral dosing of levothyroxine. Cases: We report 3 patients who presented with persistent clinical and biochemical signs of hypothyroidism despite replacement therapy with high doses of levothyroxine. Pseudomalabsorption was diagnosed by a systematic approach, including prior exclusion of digestive, liver and kidney diseases. A peroral challenge test was positive in all cases. Patients denied non-compliance, and a psychiatric approach was elusive. Two of the patients were treated successfully with a single supervised weekly 1,000-\u00b5g administration of levothyroxine, while non-supervised weekly administration resulted in hypothyroidism confirming pseudomalabsorption. Conclusions: Non-compliance with medical therapy should be considered in patients with treatment-refractory hypothyroidism. Supervised once weekly levothyroxine treatment is a safe and well-tolerated treatment option, obviating the need for parenteral administration of the drug. Apart from the medical treatment, there is also a need for psychiatric evaluation and care.<\/jats:p>","DOI":"10.1159\/000452489","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T17:02:31Z","timestamp":1479920551000},"page":"52-56","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":26,"title":["Pseudomalabsorption of Levothyroxine: A Challenge for the Endocrinologist in the Treatment of Hypothyroidism"],"prefix":"10.1530","volume":"6","author":[{"given":"Nancy","family":"Van Wilder","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bravenboer","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Herremans","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Vanderbruggen","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Velkeniers","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"2026070713070004100_ref1","unstructured":"Lips DJ, van Reisen MT, Voigt V, Venekamp W: Diagnosis and treatment of levothyroxine pseudomalabsorption. Neth J Med 2004;62:114-118."},{"key":"2026070713070004100_ref2","doi-asserted-by":"crossref","unstructured":"Ain KB, Refetoff S, Fein HG, Weintraub BD: Pseudomalabsorption of levothyroxine. JAMA 1991;266:2118-2120.","DOI":"10.1001\/jama.1991.03470150090036"},{"key":"2026070713070004100_ref3","doi-asserted-by":"crossref","unstructured":"Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH: Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987;316:764-770.","DOI":"10.1056\/NEJM198703263161302"},{"key":"2026070713070004100_ref4","doi-asserted-by":"crossref","unstructured":"Morris JC: How do you approach the problem of TSH elevation in a patient on high-dose thyroid hormone replacement? Clin Endocrinol (Oxf) 2009;70:671-673.","DOI":"10.1111\/j.1365-2265.2009.03536.x"},{"key":"2026070713070004100_ref5","doi-asserted-by":"crossref","unstructured":"Mandel SJ, Brent GA, Larsen PR: Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502.","DOI":"10.7326\/0003-4819-119-6-199309150-00009"},{"key":"2026070713070004100_ref6","doi-asserted-by":"crossref","unstructured":"Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F: Delayed intestinal absorption of levothyroxine. Thyroid 1995;5:249-253.","DOI":"10.1089\/thy.1995.5.249"},{"key":"2026070713070004100_ref7","doi-asserted-by":"crossref","unstructured":"Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A: Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med 2010;170:1996-2003.","DOI":"10.1001\/archinternmed.2010.436"},{"key":"2026070713070004100_ref8","doi-asserted-by":"crossref","unstructured":"Eledrisi MS, Szymajda A, Alshanti M, Urban RJ: Noncompliance with medical treatment: pseudomalabsorption of levothyroxine. South Med J 2001;94:833-836.","DOI":"10.1097\/00007611-200194080-00017"},{"key":"2026070713070004100_ref9","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Torres M, Varsavsky M, Alonso G: Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid 2006;16:1171-1173.","DOI":"10.1089\/thy.2006.16.1171"},{"key":"2026070713070004100_ref10","doi-asserted-by":"crossref","unstructured":"Ogawa D, Otsuka F, Mimura U, Ueno A, Hashimoto H, Kishida M, Ogura T, Makino H: Pseudomalabsorption of levothyroxine: a case report. Endocr J 2000;47:45-50.","DOI":"10.1507\/endocrj.47.45"},{"key":"2026070713070004100_ref11","doi-asserted-by":"crossref","unstructured":"Hays MT: Localization of human thyroxine absorption. Thyroid 1991;1:241-248.","DOI":"10.1089\/thy.1991.1.241"},{"key":"2026070713070004100_ref12","doi-asserted-by":"crossref","unstructured":"Molines L, Fromont I, Morlet-Barla N, Nogueira JP, Val\u00e9ro R, Vialettes B: &lt;span style=\"font-variant:small-caps; text-transform:lowercase\"&gt;L&lt;\/span&gt;-Levothyroxine pseudomalabsorption: a factitious disease. Presse Med 2007;36:1390-1394.","DOI":"10.1016\/j.lpm.2006.09.024"},{"key":"2026070713070004100_ref13","doi-asserted-by":"crossref","unstructured":"Livadariu E, Valdes-Socin H, Burlacu MC, Vulpoi C, Daly AF, Beckers A: Pseudomalabsorption of thyroid hormones: case report and review of the literature. Ann Endocrinol (Paris) 2007;68:460-463.","DOI":"10.1016\/j.ando.2007.09.003"},{"key":"2026070713070004100_ref14","unstructured":"Junglee NA, Scanlon MF, Rees DA: Increasing levothyroxine requirements in primary hypothyroidism: don't forget the urinalysis! J Postgrad Med 2006;52:201-203."},{"key":"2026070713070004100_ref15","doi-asserted-by":"crossref","unstructured":"Watts NB, Blevins LS Jr: Endocrinology. JAMA 1994;271:1666-1668.","DOI":"10.1001\/jama.1994.03510450038021"},{"key":"2026070713070004100_ref16","doi-asserted-by":"crossref","unstructured":"Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al: Levothyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787-1795.","DOI":"10.1056\/NEJMoa043903"},{"key":"2026070713070004100_ref17","doi-asserted-by":"crossref","unstructured":"Jauk B, Mikosch P, Gallowitsch HJ, Kresnik E, Molnar M, Gomez I, Lind P: Unusual malabsorption of levothyroxine. Thyroid 2000;10:93-95.","DOI":"10.1089\/thy.2000.10.93"},{"key":"2026070713070004100_ref18","unstructured":"Payer J, Sladekova K, Kinova S, Cesnakova Z, Killinger Z, Krizko M, Klimes I, Langer P: Autoimmune thyroiditis with severe hypothyroidism resistant to the treatment with high peroral doses of levothyroxine: case report. Endocr Regul 2000;34:189-193."},{"key":"2026070713070004100_ref19","doi-asserted-by":"crossref","unstructured":"Goichot B, Vinzio S, Luca F, Sirlin X, Sapin R, Schlienger JL: In vivo evidence for a direct ultra-fast negative feedback of levothyroxine on TSH secretion in humans: a case of &lt;span style=\"font-variant:small-caps; text-transform:lowercase\"&gt;L&lt;\/span&gt;-levothyroxine pseudomalabsorption. Clin Endocrinol (Oxf) 2007;67:952-953.","DOI":"10.1111\/j.1365-2265.2007.02975.x"},{"key":"2026070713070004100_ref20","doi-asserted-by":"crossref","unstructured":"M\u00fcssig K, M\u00f6rike K, Klein R, Str\u00e4ter J, Georges G, H\u00e4ring HU, Schnauder G: Hypothyroidism due to pseudo-malabsorption of levothyroxine - case 12\/2009. Dtsch Med Wochenschr 2009;134:2514.","DOI":"10.1055\/s-0028-1082836"},{"key":"2026070713070004100_ref21","doi-asserted-by":"crossref","unstructured":"Pedrosa W, Santana G: Pseudomalabsorption of levothyroxine: a case report. Arq Bras Endocrinol Metabol 2005;49:308-313.","DOI":"10.1590\/S0004-27302005000200020"},{"key":"2026070713070004100_ref22","doi-asserted-by":"crossref","unstructured":"Kubota S, Fukata S, Matsuzuka F, Kuma K, Miyauchi A: Successful management of a patient with pseudomalabsorption of levothyroxine. Int J Psychiatry Med 2003;33:183-188.","DOI":"10.2190\/0YWR-8DRV-HHP4-UE2E"},{"key":"2026070713070004100_ref23","doi-asserted-by":"crossref","unstructured":"Srinivas V, Oyibo SO: Levothyroxine pseudomalabsorption and levothyroxine absorption testing using high-dose levothyroxine: a case report and discussion. Endocr Pract 2010;16:1012-1015.","DOI":"10.4158\/EP10224.CR"},{"key":"2026070713070004100_ref24","doi-asserted-by":"crossref","unstructured":"Hays MT: Absorption of oral levothyroxine in man. J Clin Endocrinol Metab 1968;28:749-756.","DOI":"10.1210\/jcem-28-6-749"},{"key":"2026070713070004100_ref25","doi-asserted-by":"crossref","unstructured":"Balla M, Jhingam RM, Rubin DJ: Rapid levothyroxine absorption testing: a case series of nonadherent patients. Int J Endocrinol Metab 2015;13:e31051.","DOI":"10.5812\/ijem.31051"},{"key":"2026070713070004100_ref26","doi-asserted-by":"crossref","unstructured":"Walker JN, Shillo P, Ibbotson V, Vincent A, Karavitaki N, Weetman AP, Wass JAH, Allahabadia A: A thyroxine absorption test followed by weekly thyroxine administration: a method to assess non-adherence to treatment. Eur J Endocrinol 2013;168:913-917.","DOI":"10.1530\/EJE-12-1035"},{"key":"2026070713070004100_ref27","doi-asserted-by":"crossref","unstructured":"Butt MI, Gupta N, Tan HL, Waheed N: Clinical application of the levothyroxine absorption test in the diagnosis of pseudo-malabsorption. J Med Case Rep 2014;2:253-255.","DOI":"10.1530\/endoabs.34.P52"},{"key":"2026070713070004100_ref28","doi-asserted-by":"crossref","unstructured":"Krahn LE, Li H, O'Connor MK: Patients who strive to be ill: factitious disorder with physical symptoms. Am J Psychiatry 2003;160:1163-1168.","DOI":"10.1176\/appi.ajp.160.6.1163"},{"key":"2026070713070004100_ref29","doi-asserted-by":"crossref","unstructured":"Gattaz WF, Dressing H, Hewer W: M\u00fcnchhausen syndrome: psychopathology and management. Psychopathology 1990;23:33-39.","DOI":"10.1159\/000284635"},{"key":"2026070713070004100_ref30","doi-asserted-by":"crossref","unstructured":"O'Shea B: Factitious disorders: the Baron's legacy. Intern J Psychiatry Clin Pract 2003;7:33-39.","DOI":"10.1080\/13651500310001040"},{"key":"2026070713070004100_ref31","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, rev. Washington, American Psychiatric Association, 2000."},{"key":"2026070713070004100_ref32","doi-asserted-by":"crossref","unstructured":"Haglund LA: Challenges in the treatment of factitious disorder: a case study. Arch Psychiatr Nurs 2009;23:53-64.","DOI":"10.1016\/j.apnu.2008.03.002"},{"key":"2026070713070004100_ref33","doi-asserted-by":"crossref","unstructured":"Grebe SK, Cooke RR, Ford HC, Fagerstr\u00f6m JN, Cordwell DP, Lever NA, Purdie GL, Feek CM: Treatment of hypothyroidism with once weekly levothyroxine. J Clin Endocrinol Metab 1997;82:870-875.","DOI":"10.1210\/jcem.82.3.3830"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/452489","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/6\/1\/52\/35681\/etj452489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/6\/1\/52\/35681\/etj452489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:44:17Z","timestamp":1783446257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/6\/1\/52\/4867\/Pseudomalabsorption-of-Levothyroxine-A-Challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000452489","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}